Amundi Asset Management US’s Denali Therapeutics DNLI Stock Holding History

Amundi Asset Management US’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$291K	Sell	5,104 -4,696	-48%	-$314K	﹤0.01%	1426
2020 Q4	$821K	Hold	9,800	–	–	﹤0.01%	1244
2020 Q3	$351K	Hold	9,800	–	–	﹤0.01%	1302
2020 Q2	$237K	Hold	9,800	–	–	﹤0.01%	1360
2020 Q1	$172K	Sell	9,800 -100	-1%	-$2.09K	﹤0.01%	1354
2019 Q4	$172K	Hold	9,900	–	–	﹤0.01%	1502
2019 Q3	$152K	Buy	9,900 +500	+5%	+$9.55K	﹤0.01%	1512
2019 Q2	$195K	Hold	9,400	–	–	﹤0.01%	1481
2019 Q1	$218K	Hold	9,400	–	–	﹤0.01%	1422
2018 Q4	$194	Buy	+9,400	New	+$171K	﹤0.01%	1394

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amundi Asset Management US's DNLI Position: Q1 2021 in Review

Amundi Asset Management US reduced its Denali Therapeutics (DNLI) stake by 48% in Q1 2021, selling an estimated $314K and leaving 5,104 shares worth $291K. The position accounts for ﹤0.01% of the portfolio, ranked #1426.

Amundi Asset Management US first reported a position in DNLI in Q4 2018 and has held it in 10 quarters since. The position peaked at $821K in Q4 2020. 217 funds tracked by Wall St. Rank hold DNLI as of Q1 2021.

Amundi Asset Management US held 5,104 shares of Denali Therapeutics worth $291K as of Q1 2021.
Amundi Asset Management US sold 4,696 Denali Therapeutics shares in Q1 2021, an estimated $314K.
Denali Therapeutics made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1426 holding.
Amundi Asset Management US first reported a position in Denali Therapeutics in Q4 2018 and has held it in 10 quarters since.
Amundi Asset Management US's Denali Therapeutics position peaked at $821K in Q4 2020.
217 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.